Month: May 2020

Scorpio Bulkers Inc. Announces Financial Results for the First Quarter of 2020 and Declares a Quarterly Cash Dividend

Written by Customer Service on May 11, 2020. Posted in Earnings Releases And Operating Results.

MONACO, May 11, 2020 (GLOBE NEWSWIRE) — Scorpio Bulkers Inc. (NYSE: SALT) (“Scorpio Bulkers” or the “Company”), today reported its results for the three months ended March 31, 2020.The Company also announced that on May 11, 2020, its Board of Directors declared a quarterly cash dividend of $0.05 per share on the Company’s common shares.Share and per share results included herein have been retroactively adjusted to reflect the one-for-ten reverse stock split of the Company’s common shares, which took effect on April 7, 2020.Results for the Three Months Ended March 31, 2020 and 2019For the first quarter of 2020, the Company’s GAAP net loss was $124.7 million, or $18.12 per diluted share, including:a non-cash loss of approximately $89.1 million and cash dividend income of $0.4 million, or $12.88 loss per diluted share, from the Company’s...

Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting

Written by Customer Service on May 11, 2020. Posted in Public Companies.

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of an oral presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting.The virtual presentation will take place on May 16, 2020 at 6:00pm ET. The abstract is currently available on the ASCRS website where the virtual presentation will be available as well.The Phase 1b clinical trial evaluated antolimab in patients with three forms of severe allergic conjunctivitis refractory to topical treatments; atopic keratoconjunctivitis, vernal keratoconjunctivitis and perennial allergic conjunctivitis. Following the presentation, the slides will...

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update

Written by Customer Service on May 11, 2020. Posted in Earnings Releases And Operating Results.

NASH-RX Clinical Trial Protocol Filed with FDA; First Patient Currently Expected to be Enrolled in Second Quarter 2020Filed a New Form S-3 Shelf Registration Statement Which Replaces the Company’s Existing Shelf Registration Statement, which Expires on June 1, 2020NORCROSS, Ga., May 11, 2020 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2020. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.Harold H. Shlevin, Ph.D., President and Chief Executive Officer of Galectin Therapeutics, said, “We are excited to have recently submitted...

Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update

Written by Customer Service on May 11, 2020. Posted in Earnings Releases And Operating Results.

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and AutoimmunityDosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid TumorsSuccessfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing FacilityStrong Cash PositionCAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported first quarter 2020 financial results and provided an overview of operational progress.“During the first quarter, we made significant progress in advancing our business by reprioritizing our therapeutic areas of focus and progressing our oncology pipeline of Red Cell Therapeutics™, including the dosing of...

American Shared Hospital Services Reports First Quarter 2020 Results

Written by Customer Service on May 11, 2020. Posted in Earnings Releases And Operating Results.

COVID-19 Pandemic had Modest Impact on Gamma Knife VolumesSAN FRANCISCO, CA, May 11, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the first quarter ended March 31, 2020.First Quarter HighlightsTotal revenue in the first quarter was $4,568,000, a decline of 14.2% from the comparable period in 2019. Proton therapy revenue of $1,676,000 increased 2.1% compared to the first quarter of 2019. Gamma Knife revenue of $2,892,000 declined 15.2% compared to the first quarter of 2019 due to lower average reimbursement at the Company’s retail sites. Total proton therapy fractions in the first quarter increased 8.4% compared...

Assertio Therapeutics Announces First-Quarter 2020 Results

Written by Customer Service on May 11, 2020. Posted in Earnings Releases And Operating Results.

— Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million —— Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt —— Merger with Zyla Life Sciences On Track and Expected to Close Shortly After the Company’s 2020 Annual Meeting on May 19, 2020 —LAKE FOREST, Ill., May 11, 2020 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today reported financial results for the quarter ended March 31, 2020 and provided an update on its business performance and strategic initiatives.First-Quarter Financial Highlights:(unaudited)(1) All non-GAAP measures included in this earnings release are reconciled to the corresponding GAAP measures in the schedules attached.“Today we reported positive results in a truly...

Allakos Reports First Quarter 2020 Financial Results

Written by Customer Service on May 11, 2020. Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) — Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020.First Quarter 2020 Financial ResultsResearch and development expenses were $18.3 million in the first quarter of 2020 as compared to $15.1 million in the same period in 2019, an increase of $3.2 million.General and administrative expenses were $11.6 million in the first quarter of 2020 as compared to $5.8 million in the same period in 2019, an increase of $5.8 million.Allakos reported a net loss of $27.8 million in the first quarter of 2020 as compared to $20.0 million in the same period in 2019, an increase of $7.8 million. Net loss per basic...

Catalyst Biosciences Reports First Quarter 2020 Operating & Financial Results and Provides a Corporate Update

Written by Customer Service on May 11, 2020. Posted in Earnings Releases And Operating Results.

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedbackDalcA Phase 2b study completed, final data to be presented in the second quarterSOUTH SAN FRANCISCO, Calif., May 11, 2020 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2020 and provided a corporate update.“Despite disruptions in clinical and preclinical research operations affecting the biotechnology industry as the result of the COVID-19 pandemic, we have continued to make significant progress in both our MarzAA and DalcA programs,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We have incorporated guidance from FDA and EMA in our Phase 3 trial design for MarzAA and anticipate enrolling...

TRHC and ASCP Sign Letter of Intent to offer MedWise™ to Consultant Pharmacists

Written by Customer Service on May 11, 2020. Posted in Public Companies.

MOORESTOWN, N.J., May 11, 2020 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare®, Inc. (TRHC) (Nasdaq: TRHC), a healthcare technology company advancing the field of medication safety, today announces it has signed a Letter of Intent with ASCP, a membership association that represents pharmacists, healthcare professionals and students serving the unique medication needs of older adults. The first of its kind, the strategic collaboration will jointly offer TRHC’s medication safety software, MedWise™, available to the pharmacist membership of ASCP. The principal value proposition of the collaboration is a working partnership between TRHC and ASCP to improve medication safety in patients who have a high burden of disease and complex medication regimens, while also developing consultant pharmacist workflow recommendations for its use.According...

Xebec Welcomes Mr. Peter Bowie as Advisor to its Board of Directors

Written by Customer Service on May 11, 2020. Posted in Public Companies.

MONTREAL, May 11, 2020 (GLOBE NEWSWIRE) — Xebec Adsorption Inc. (TSXV: XBC) (“Xebec”), a global provider of clean energy solutions is pleased to announce today that Mr. Peter Bowie will be providing strategic, corporate finance and audit advice to its Board of Directors and management. He will also be nominated to the company’s board of directors at this years’ annual general meeting in June.Mr. Bowie is currently a board member and a member of the Audit Committee of Magna International Inc. He brings financial expertise, a dedication to governance and audit excellence, a strong understanding of strategy and risk, as well as detailed insight of political and economic dynamics within China.He previously served as the Chief Executive of Deloitte China from 2003 to 2008, as well as senior partner and a member of the Board and the management...

Month: May 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals